We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

The Neuroeconomics of Behavioral Therapies for Adolescent Substance Abuse (Imaging)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01093898
Recruitment Status : Completed
First Posted : March 26, 2010
Last Update Posted : November 1, 2017
Sponsor:
Collaborators:
Information provided by (Responsible Party):

Study Description
Brief Summary:
This study will measure the brain activity of adolescent substance abusers while they make decisions about their preferences to receive smaller, immediate rewards versus larger delayed rewards. The investigators expect that patterns of brain activity while engaged in this decision making task will predict response to treatment among adolescent substance users. The investigators expect to use the results of this study to develop more effective treatments for adolescent substance abuse

Condition or disease
Adolescent Substance Use

  Show Detailed Description

Study Design

Study Type : Observational
Actual Enrollment : 51 participants
Observational Model: Family-Based
Time Perspective: Prospective
Official Title: The Neuroeconomics of Behavioral Therapies for Adolescent Substance Abuse
Study Start Date : April 2010
Primary Completion Date : May 2014
Study Completion Date : May 2014
Groups and Cohorts

Group/Cohort
No intervention


Outcome Measures

Primary Outcome Measures :
  1. delay discounting [ Time Frame: Assessed at baseline ]
    laboratory task assessing preference for immediate rewards


Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   12 Years to 18 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
Adolescents recruited into the Marijuana Trial and the Alcohol Trial during the period of the R21 project would participate in a single neuroimaging session as soon after the intake session as possible.
Criteria

Inclusion Criteria:

  • Participants must be 12 to 18 years old and have a parent/guardian who can participate.
  • Youth must meet either of the following inclusion criteria:

    1. Report using marijuana during the previous 30 days or provide a marijuana-positive urine test, plus meet criteria for Cannabis Abuse or Dependence OR
    2. Meet Diagnostic Statistical Manual (DSM) criteria for Alcohol Abuse or dependence or have had one binge episode, specified by ≥5 drinks in one day, in the past 90 days and report alcohol use in the past 30 days.

Exclusion Criteria:

  • Contraindications to MRI including ferromagnetic implants or claustrophobia
  • Meeting DSM criteria for dependence on illicit drugs other than marijuana or alcohol (use/abuse of other drugs will not be excluded)
  • Exhibit active psychosis, have severe medical or psychiatric illness limiting participation
  • Are pregnant or breast-feeding.
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01093898


Locations
United States, New Hampshire
Geisel School of Medicine at Dartmouth
Lebanon, New Hampshire, United States, 03756
Sponsors and Collaborators
Dartmouth-Hitchcock Medical Center
National Institutes of Health (NIH)
National Institute on Drug Abuse (NIDA)
Investigators
Principal Investigator: Catherine Stanger, Ph.D. Dartmouth College
More Information

Publications:
Responsible Party: Dartmouth-Hitchcock Medical Center
ClinicalTrials.gov Identifier: NCT01093898     History of Changes
Other Study ID Numbers: 36824
1R21DA029442-01 ( U.S. NIH Grant/Contract )
First Posted: March 26, 2010    Key Record Dates
Last Update Posted: November 1, 2017
Last Verified: October 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Additional relevant MeSH terms:
Substance-Related Disorders
Chemically-Induced Disorders
Mental Disorders